Combined aPproach to treatment using ranibizumab and efalizumab for diabetic macular edema study: The CAPTURE DME study

Trial Profile

Combined aPproach to treatment using ranibizumab and efalizumab for diabetic macular edema study: The CAPTURE DME study

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Efalizumab (Primary) ; Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Acronyms CAPTURE DME
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 04 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top